Wall Street Zen Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Sell

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also recently commented on MIST. Wells Fargo & Company upped their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Milestone Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $8.00.

Milestone Pharmaceuticals Trading Down 6.8%

MIST opened at $2.04 on Friday. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The company’s 50 day moving average price is $2.23 and its two-hundred day moving average price is $1.97. The firm has a market capitalization of $173.75 million, a price-to-earnings ratio of -2.49 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. As a group, research analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Insider Buying and Selling at Milestone Pharmaceuticals

In related news, CEO Joseph Oliveto sold 43,000 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $2.25, for a total value of $96,750.00. Following the transaction, the chief executive officer owned 303,721 shares of the company’s stock, valued at approximately $683,372.25. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Simplify Asset Management Inc. grew its stake in shares of Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in Milestone Pharmaceuticals by 553.5% during the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares during the last quarter. Bay Rivers Group purchased a new position in Milestone Pharmaceuticals during the second quarter worth about $28,000. Sapient Capital LLC bought a new stake in Milestone Pharmaceuticals in the 3rd quarter worth about $25,000. Finally, AMH Equity Ltd purchased a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at about $463,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.